{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:56Z","timestamp":1793176796148,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacl.2026.03.014","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:59:34Z","timestamp":1774583974000},"page":"1086-1096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing treatment in homozygous familial hypercholesterolemia: Monocentric observational clinical study on efficacy and safety of evinacumab and lomitapide combination"],"prefix":"10.1016","volume":"20","author":[{"given":"Marta","family":"Biolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Marodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1686-5319","authenticated-orcid":false,"given":"Camilla","family":"Portinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7096-5201","authenticated-orcid":false,"given":"Alberto","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Bertocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Previato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-7441","authenticated-orcid":false,"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.03.014_bib1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.03.014_bib2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.03.014_bib3","first-page":"398","article-title":"Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association","volume":"14","author":"Brown","year":"2020","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"key":"10.1016\/j.jacl.2026.03.014_bib4","first-page":"1819","article-title":"Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)","volume":"34","author":"Tarugi","year":"2024","journal-title":"Nutr\u00a0Metab\u00a0Cardiovasc\u00a0Dis"},{"key":"10.1016\/j.jacl.2026.03.014_bib5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.03.014_bib6","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.03.014_bib7","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"384","author":"Luo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.03.014_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.03.014_bib9","first-page":"1843","article-title":"From lipoprotein apheresis to proprotein convertase subtilisin\/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients","volume":"25","author":"Zenti","year":"2018","journal-title":"Eur\u00a0J\u00a0Prev\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.03.014_bib10","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia\u2014brief report","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.03.014_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.03.014_bib12","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.03.014_bib13","first-page":"832","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur\u00a0J\u00a0Prev\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.03.014_bib14","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.03.014_bib15","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.03.014_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100648","article-title":"The long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia","volume":"2","author":"Raal","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacl.2026.03.014_bib17","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.atherosclerosissup.2021.01.007","article-title":"How registers could enhance knowledge and characterization of genetic dyslipidaemias: the experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia","volume":"42","author":"Gazzotti","year":"2020","journal-title":"Atheroscler\u00a0Suppl"},{"key":"10.1016\/j.jacl.2026.03.014_bib18","first-page":"880","article-title":"Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study","volume":"12","author":"Masana","year":"2024","journal-title":"Lancet Diabetes\u00a0Endocrinol"},{"key":"10.1016\/j.jacl.2026.03.014_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.07.014","article-title":"Sex-specific predictors of PCSK9 levels in a European population: the IMPROVE study","volume":"309","author":"Ferri","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.03.014_bib20","first-page":"2251","article-title":"Angiopoietin-like 3 and subclinical peripheral arterial disease: evidence from the Brisighella Heart Study","volume":"27","author":"Ruscica","year":"2020","journal-title":"Eur\u00a0J\u00a0Prev\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.03.014_bib21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hep.20081","article-title":"Hy's law","volume":"39","author":"Reuben","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2026.03.014_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacl.2026.03.014_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120627","article-title":"Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia","volume":"413","author":"Rosenson","year":"2026","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.03.014_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.03.014_bib25","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/ATVBAHA.123.320609","article-title":"Evinacumab and cardiovascular outcome in patients with homozygous familial hypercholesterolemia","volume":"44","author":"Beliard","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.03.014_bib26","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/ATVBAHA.124.322364","article-title":"Real-world effectiveness and safety of evinacumab in children and adults with homozygous familial hypercholesterolemia: a multisite US perspective\u2014brief report","volume":"45","author":"Wilkinson","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.03.014_bib27","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s12325-025-03160-4","article-title":"Evinacumab for homozygous familial hypercholesterolemia: the Italian Cohort of the ELIPSE HoFH Study","volume":"42","author":"Iannuzzo","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2026.03.014_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.03.014_bib29","article-title":"Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH registry","volume":"12","author":"Cuchel","year":"2023","journal-title":"J\u00a0Am\u00a0Heart Assoc"},{"key":"10.1016\/j.jacl.2026.03.014_bib30","first-page":"1038","article-title":"Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry","volume":"31","author":"D'Erasmo","year":"2024","journal-title":"Eur\u00a0J\u00a0Prev\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.03.014_bib31","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.jacc.2025.04.005","article-title":"Homozygous familial hypercholesterolemia is a life-limiting condition: medical life-trajectories in the post-2010 era","volume":"85","author":"Mulder","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.03.014_bib32","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.03.014_bib33","first-page":"e261","article-title":"Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3","volume":"18","author":"Zimerman","year":"2024","journal-title":"J\u00a0Clin\u00a0Lipidol"}],"updated-by":[{"DOI":"10.1016\/j.jacl.2026.07.020","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000}},{"DOI":"10.1016\/j.jacl.2026.07.020","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:43:51Z","timestamp":1780785831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1933287426000899"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.014","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing treatment in homozygous familial hypercholesterolemia: Monocentric observational clinical study on efficacy and safety of evinacumab and lomitapide combination","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}